Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Gray matter involvement in multiple sclerosis.
A hematopoietic contribution to microhemorrhage formation during antiviral CD8 T cell-initiated blood-brain barrier disruption.
The influence of tetracyclines on T cell activation.
Merck KGaA to try again to get approval for MS pill cladribine
Estimated incidence of multiple sclerosis among United States Armed Forces personnel using the Defense Medical Surveillance System.
Placebo Cohorts in Phase-3 MS Treatment Trials - Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data.
Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned.
Top 10 Research Questions Related to Physical Activity and Multiple Sclerosis.
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat.
Ustekinumab approved for psoriatic arthritis in US, Europe
[Functional MRI during the execution of a motor task in patients with multiple sclerosis and fatigue.]
Associations of alcohol consumption with clinical and MRI measures in multiple sclerosis.
Overview of the biology of type I interferons.
Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis.
The co-occurrence of multiple sclerosis and type 1 diabetes: Shared aetiologic features and clinical implication for MS aetiology.
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Riluzole attenuates excitatory amino acid transporter type 3 activity in Xenopus oocytes via protein kinase C inhibition.
Th17 Cells: Biology, Pathogenesis of Autoimmune and Inflammatory Diseases, and Therapeutic Strategies.
Multiple sclerosis and glutamate excitotoxicity.
Non-local robust detection of DTI white matter differences with small databases.
Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?
Simvastatin: a review.
Secukinumab: first global approval.
Pages
« first
‹ previous
…
169
170
171
172
173
174
175
176
177
…
next ›
last »